Home care with acupuncture increased the quality of life in a patient with advanced cancer with neuropathic pain induced by bone metastasis: a case report

Publication date: Available online 12 April 2018 Source:Journal of Integrative Medicine Author(s): Ching-Feng Su A 66-year-old female patient was diagnosed with hepatocellular carcinoma accompanied by neuropathic pain induced by a metastatic tumor that compromised root and spinal canal. Although her pain was relieved following medical treatment, breakthrough pain occurring 1–2 times a day was still distressing. Neuropathic pain in her right lower limb caused discomfort and irritability and decreased her quality of life. We had limited options to adjust her prescription drug regime, due to the side effect of these drugs. Although acupuncture therapy was only performed at her home once a week, the efficacy was outstanding. The patient did not report any further instances of breakthrough pain, and she did not require additional bolus morphine. She could comfortably live in her familiar surroundings with her family and did not require any emergency room visits or admission into the hospital during the last month of her life. She had excellent quality of life in the terminal period of her life, and could even participate in a family function during this time. The present case report suggests that acupuncture may have a role in treating neuropathic pain induced by bone metastasis in patients with advanced cancer across clinical and in-home settings.
Source: Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research

Related Links:

Publication date: May 2018Source: Journal of Integrative Medicine, Volume 16, Issue 3Author(s): Ching-Feng SuAbstractA 66-year-old female patient was diagnosed with hepatocellular carcinoma accompanied by neuropathic pain induced by a metastatic tumor that compromised root and spinal canal. Although her pain was relieved following medical treatment, breakthrough pain occurring 1–2 times a day was still distressing. Neuropathic pain in her right lower limb caused discomfort and irritability and decreased her quality of life. We had limited options to adjust her prescription drug regime, due to the side effect of these...
Source: Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
ConclusionLaparoscopic extended cholecystectomy is technically feasible in patients with T3 GBC, and the extent of resection is the same as that of open surgery.
Source: Surgical Endoscopy - Category: Surgery Source Type: research
Authors: Yang G, Pan Z, Ma N, Qu L, Yuan T, Pang X, Yang X, Dong L, Liu S Abstract Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare and malignant form of lung cancer with a poor prognosis for patients. The common sites of metastases are the liver, adrenal glands, bone and brain. LCNEC rarely metastasizes to the small intestine, ovaries, tonsils, mandible, vulva or spine. To the best of our knowledge, there have been no reports of leptomeningeal metastasis of LCNEC to date. The present case report describes an unusual case of leptomeningeal metastasis from pulmonary LCNEC alongside a review of the lit...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In this study, we focused on two pathways of cardiomyocytes or heart cells: the Hippo pathway, which is involved in stopping renewal of adult cardiomyocytes, and the dystrophin glycoprotein complex (DGC) pathway, essential for cardiomyocyte normal functions." Previous work had hinted that components of the DGC pathway may somehow interact with members of the Hippo pathway. The researchers genetically engineered mice to lack genes involved in one or both pathways, and then determined the ability of the heart to repair an injury. These studies showed for the first time that dystroglycan 1, a component of the DGC ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
From portable genome sequencers until genetic tests revealing distant relations with Thomas Jefferson, genomics represents a fascinatingly innovative area of healthcare. As the price of genome sequencing has been in free fall for years, the start-up scene is bursting from transformative power. Let’s look at some of the most amazing ventures in genomics! The amazing journey of genome sequencing Genome sequencing has been on an amazing scientific as well as economic journey for the last three decades. The Human Genome Project began in 1990 with the aim of mapping the whole structure of the human genome and sequencing ...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Genomics Personalized Medicine AI artificial intelligence bioinformatics cancer DNA dna testing DTC gc3 genetic disorders genetics genome sequencing personal genomics precision medicine Source Type: blogs
1070Non-seminomatous mixed (NSM) germ cell tumors (GCT) have varying percentages of malignant tumor (embryonal carcinoma, yolk sac tumor, choriocarcinoma) and teratoma (hair, teeth, bone; brain, thyroid, liver, lung tissue).1 Radical orchiectomy is initial treatment and provides histologic characterization, treatment individualized by histology and if tumor markers [alpha fetoprotein (AFP), beta subunit of human chorionic gonadotropin (beta-hCG), and lactate dehydrogenase (LDH)] normalize after orchiectomy. Initial staging is computed tomography (CT) for retroperitoneal lymphadenopathy or distant lung metastasis. 2-deoxy-2...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Posters Source Type: research
By Stacy SimonThe US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) to treat people with head and neck squamous cell carcinoma that has spread or come back after previous chemotherapy treatment. It’s the first immunotherapy drug approved for head and neck cancer. Keytruda is already approved for melanoma and non-small cell lung cancer.The FDA based its approval on a clinical trial of 174 people with head and neck squamous cell carcinoma that had spread or come back after they were treated with platinum-based chemotherapy. Tumors shrank or disappeared in 16% of the participants who were given...
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Oral Cavity and Oropharyngeal Cancer Source Type: news
We report a case of a 44-year-old man with a localized right renal pelvis mass treated with a right nephroureterectomy. The pathological examination showed a high-grade urothelial carcinoma of the renal pelvis, stage III (pT3aNxM0). A few days later, he developed lower back pain, hematuria, cough with hemoptoic sputum and progressive dyspnea. Radiological explorations showed multiple bilateral lung nodules and a retroperitoneal mass. A CT-guided biopsy of the retroperitoneal mass revealed a high-grade angiosarcoma. A review of the nephrectomy specimen showed a microscopic focus of angiosarcoma in the urothelial carcinoma. ...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Publication date: Available online 8 January 2016 Source:Journal of Clinical Neuroscience Author(s): C. Rory Goodwin, Nancy Abu-Bonsrah, Christine Boone, Alejandro Ruiz-Valls, Eric W. Sankey, Rachel Sarabia-Estrada, Benjamin D. Elder, Thomas Kosztowski, Daniel M. Sciubba Metastases to the spine from non-hepatocellular carcinomas, such as cholangiocarcinoma and angiosarcoma, occur rarely. With improvements in oncologic care, the number of patients diagnosed with metastatic cancer is expected to increase. We performed a systematic review of the literature to assess the clinical presentation, treatment, outcome and...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Background: MRX34 is a liposomal nanoparticle formulation with an encapsulated mimic of the naturally occurring microRNA-34 (miR-34), which is lost or expressed at reduced levels in many tumors. miR-34 inhibits key oncogenic pathways by repressing multiple important oncogenes including BCL2, E2F3, HDAC1, MET, MEK1, CDK4/6, PDGFR-a/β, SIRT1, WNT1/3, NOTCH-1, β-catenin, CD44, Nanog and AXL. miR-34 also represses the expression of PD-L1 and DGK, thereby possibly triggering an anti-tumor immune response and cancer cell death. A multicenter Phase 1 clinical trial of MRX34 is being conducted in patients with advanced m...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Clinical Trials: Poster Presentations - Proffered Abstracts Source Type: research
More News: Acupuncture | Back Pain | Brain | Cancer | Cancer & Oncology | Carcinoma | Complementary Medicine | Emergency Medicine | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Morphine | Neurology | Pain